Inactive Instrument

Press Releases Tetra Bio Pharma Inc Canadian Securities Exchange

Equities

Acute Pain Pipeline, Clinical and Non-Clinical Stages Products, and FDA Approvals 2023 (Updated)	23-09-27	AQ
Tetra Bio-Pharma Announces Listing to OTCPink Market	23-02-10	PR
REDUVO™ Marketing Approval on the Right Path	22-12-22	PR
Tetra Bio-Pharma Announces Results of Artificial Intelligence Study of ARDS-003 Combined with Favipiravir	22-12-06	PR
Tetra Bio-Pharma Provides Update on Patent Applications for Novel Therapeutic ARDS-003	22-11-29	PR
Tetra Bio-Pharma Inc. Announces Second Closing of Financing with Alpha Blue Ocean	22-10-27	PR
Tetra Collaborates with Cellvera to Develop a Potential Oral Combination Treatment for COVID-19 Patients	22-09-06	PR
Tetra Bio-Pharma Announces Positive Preclinical Results of ARDS-003, a Novel Therapeutic for Sepsis and Viral Infections	22-08-10	PR
Tetra Bio-Pharma Appoints Chief Financial Officer	22-05-30	PR
Tetra Bio-Pharma Receives $4.5M from the Ministère de l'Économie et de l'Innovation/Investissement Québec	22-02-16	PR
Tetra Bio-Pharma Enters into a Strategic Partnership with Avicanna	22-02-14	PR
QIXLEEF™ Aerosol Meets the Criteria Established by the U.S. FDA for Delivery of Inhalation Aerosols	21-11-29	PR
Tetra Bio-Pharma Inc. Announces Termination of "At-The-Market" Offering	21-11-04	PR
Tetra Bio Pharma : Receives Positive Opinion for Orphan Drug Designation for QIXLEEF™ from the European Medicines Agency	21-10-21	PR
Tetra Bio Pharma : REDUVO™ - A Major Milestone for Tetra Bio-Pharma Inc.	21-10-05	PR

No results for this search